Otsuka America Pharmaceutical, Inc.
2440 Research Boulevard
About Otsuka America Pharmaceutical, Inc.Otsuka is a successful, global group of affiliated companies that discovers, develops and markets innovative products. In the U.S., Otsuka is hard at work investigating potential new treatments, with numerous compounds in various stages of development to treat disorders of the cardiovascular, gastrointestinal, respiratory, renal and central nervous systems, and to treat cancer and ophthalmic disorders. Our pharmaceutical products include ABILIFY® (aripiprazole) Tablets and intramuscular injection, IV BUSULFEX® (busulfan) Injection and PLETAL® (cilostazol) Tablets, although we no longer actively market PLETAL. We also have the BreathTek™ Urea Breath Test for H. pylori. We have numerous additional products in our pipeline that are currently under development. We are highly diversified, with pharmaceutical as well as consumer products such as Crystal Geyser Water, NatureMade® Vitamins, Ridge Wines, and diagnostic equipment.
Please visit our website at www.otsuka-us.com for more information.
32 articles with Otsuka America Pharmaceutical, Inc.
UK's National Institute for Clinical Excellence (NICE) Wants More Data on Bristol-Myers Squibb Company And Otsuka America Pharmaceutical, Inc. Schizophrenia Drug Abilify
Bristol-Myers Squibb Company Announces Extension of U.S. Agreement for ABILIFY(R) and Establishment of an Oncology Collaboration with Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring
Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer
Otsuka America Pharmaceutical, Inc. Release: American Psychiatric Association Announces Recipients of 2008 Awards for Advancing Minority Mental Health; Awards Honoring Mental Health Programs Supported by a Grant from Otsuka America Pharmaceutical, Inc.
EVEREST Data Use of Otsuka America Pharmaceutical, Inc.'s Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACC's Late Breaking Clinical Trials
Bristol-Myers Squibb Company Release: ABILIFY(R) (Aripiprazole) Injection For Intramuscular Use For Adults With Agitation Associated With Schizophrenia Or Bipolar Mania Now Available
Summit Corporate Services, Inc. To Provide Clinical Trial Monitoring Services For Otsuka America Pharmaceutical, Inc.
Emory Heart Center Researchers Present CREST Study Findings At AHA Scientific Sessions: Cilostazol Reduces Coronary Artery Stent Restenosis By 40 Percent